Lowest Price Guaranteed
Pages
185
Last Updated
July 2026
View Count
11234
1. BACKGROUND
1.1. Context
1.2. Project Objectives
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis
6. INTRODUCTION
6.1. Overview of Cancer Metabolism-Based Therapies
6.2. Key Metabolic Alterations Associated with Cancer Cells
6.3. Core Metabolic Pathways Associated with Cancer
6.4. Advantages of Cancer Metabolism-Based Therapies
6.5. Challenges Associated with Cancer Metabolism-Based Therapies
6.6. Future Outlook
7. MARKET LANDSCAPE
7.1. Methodology and Key Parameters
7.2. Cancer Metabolism-Based Therapies: Overall Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Metabolic Pathway
7.2.3. Analysis by Target
7.2.4. Analysis by Target Disease Indication
7.2.5. Analysis by Route of Administration
7.2.6. Analysis by Type of Modality
7.2.7. Analysis by Type of Therapy
7.2.8. Analysis by Drug Designation
7.3. Cancer Metabolism-Based Therapies: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Company Size and Location of Headquarters
7.3.5. Most Active Players: Analysis by Number of Therapies Developed
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. AstraZeneca
8.2.1. Company Details
8.2.2. Cancer Metabolism-Based Drugs Portfolio
8.2.3. Key Initiatives
8.3. Bristol Myers Squibb
8.3.1. Company Details
8.3.2. Cancer Metabolism-Based Drugs Portfolio
8.3.3. Key Initiatives
8.4. Cornerstone Pharmaceuticals
8.4.1. Company Details
8.4.2. Cancer Metabolism-Based Drugs Portfolio
8.4.3. Key Initiatives
8.5. Eli Lilly
8.5.1. Company Details
8.5.2. Cancer Metabolism-Based Drugs Portfolio
8.5.3. Key Initiatives
8.6. Novartis
8.6.1. Company Details
8.6.2. Cancer Metabolism-Based Drugs Portfolio
8.6.3. Key Initiatives
8.7. Polaris
8.7.1. Company Details
8.7.2. Cancer Metabolism-Based Drugs Portfolio
8.7.3. Key Initiatives
8.8. Roche
8.8.1. Company Details
8.8.2. Cancer Metabolism-Based Drugs Portfolio
8.8.3. Key Initiatives
8.9. Servier
8.9.1. Company Details
8.9.2. Cancer Metabolism-Based Drugs Portfolio
8.9.3. Key Initiatives
9. CLINICAL TRIAL ANALYSIS
9.1. Methodology and Key Parameters
9.2. Cancer Metabolism-Based Therapies: Clinical Trial Analysis
9.2.1. Analysis by Trial Registration Year
9.2.2. Analysis by Trial Status
9.2.3. Analysis by Trial Registration Year and Trial Status
9.2.4. Analysis by Number of Patients Enrolled and Trial Registration Year
9.2.5. Analysis by Number of Patients Enrolled and Trial Status
9.2.6. Analysis by Trial Phase
9.2.7. Analysis by Number of Patients Enrolled and Trial Phase
9.2.8. Analysis by Study Design
9.2.8.1. Analysis by Design Masking
9.2.8.2. Analysis by Type of Intervention Model
9.2.8.3. Analysis by Trial Purpose
9.2.8.4. Analysis by Type of Allocation
9.2.9. Analysis by Type of Sponsor / Collaborator
9.2.10. Analysis by Patient Gender
9.2.11. Most Active Industry Players: Analysis by Number of Clinical Trials
9.2.12. Most Active Non-Industry Players: Analysis by Number of Clinical Trials
9.2.13. Analysis by Geography
9.2.13.1. Analysis of Clinical Trials by Trial Status, Trial Phase and Geography
9.2.13.2. Analysis of Clinical Trials by Trial Status and Geography
9.2.13.3. Analysis of Clinical Trials by Patients Enrolled, Trial Status and Geography
9.2.14. Geographical Distribution of Trials and Number of Patients Enrolled
9.2.14.1. Clinical Trials in North America: Key Insights
9.2.14.2. Clinical Trials in Europe: Key Insights
9.2.14.3. Clinical Trials in Asia-Pacific: Key Insights
9.2.14.4. Clinical Trials in Rest of the World: Key Insights
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Partnership Models
10.2. Cancer Metabolism-Based Therapies: Partnerships and Collaborations
10.2.1. Analysis by Year of Partnership
10.2.2. Analysis by Type of Partnership
10.2.3. Analysis by Year and Type of Partnership
10.2.4. Analysis by Target Disease Indication
10.2.5. Most Active Players: Analysis by Number of Partnerships
10.2.6. Analysis by Geography
10.2.6.1. Local and International Deals
10.2.6.2. Intercontinental and Intracontinental Deals
11. MARKET IMPACT ANALYSIS
11.1. Chapter Overview
11.2. Market Drivers
11.3. Market Restraints
11.4. Market Opportunities
11.5. Market Challenges
12. GLOBAL CANCER METABOLISM-BASED THERAPIES MARKET
12.1. Forecast Methodology
12.2. Key Assumptions
12.3. Forecast Methodology
12.4. Global Cancer Metabolism-Based Therapies Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
12.5. Multivariate Scenario Analysis
12.5.1. Global Cancer Metabolism-Based Therapies Market, Forecasted Estimates (Till 2035), Conservative Scenario
12.5.2. Global Cancer Metabolism-Based Therapies Market, Forecasted Estimates (Till 2035), Optimistic Scenario
12.6. Key Market Segmentations
13. CANCER METABOLISM-BASED THERAPIES MARKET, BY TYPE OF MODALITY
13.1. Cancer Metabolism-Based Therapies Market: Distribution by Type of Modality
13.1.1. Cancer Metabolism-Based Therapies Market for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
13.1.2. Cancer Metabolism-Based Therapies Market for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
13.2. Data Triangulation and Validation
14. CANCER METABOLISM-BASED THERAPIES MARKET, BY ROUTE OF ADMINISTRATION
14.1. Cancer Metabolism-Based Therapies Market: Distribution by Route of Administration
14.1.1. Cancer Metabolism-Based Therapies Market for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
14.1.2. Cancer Metabolism-Based Therapies Market for Intramuscular Route: Forecasted Estimates (Till 2035)
14.1.3. Cancer Metabolism-Based Therapies Market for Intravenous Route: Forecasted Estimates (Till 2035)
14.2. Data Triangulation and Validation
15. CANCER METABOLISM-BASED THERAPIES MARKET: BY TARGET DISEASE INDICATION
15.1.1. Cancer Metabolism-Based Therapies Market for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
15.1.2. Cancer Metabolism-Based Therapies Market for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
15.1.3. Cancer Metabolism-Based Therapies Market for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
15.1.4. Cancer Metabolism-Based Therapies Market for Brain Cancer: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)
15.1.5. Cancer Metabolism-Based Therapies Market for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
15.1.6. Cancer Metabolism-Based Therapies Market for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
15.1.7. Cancer Metabolism-Based Therapies Market for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
15.1.8. Cancer Metabolism-Based Therapies Market for Malignant-mesothelioma: Forecasted Estimates (Till 2035)
15.1.9. Cancer Metabolism-Based Therapies Market for Pancreatic Cancer: Forecasted Estimates (Till 2035)
15.1.10. Cancer Metabolism-Based Therapies Market for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035)
15.1.11. Cancer Metabolism-Based Therapies Market for Hepatocellular Carcinoma: Forecasted Estimates (Till 2035)
15.2. Data Triangulation and Validation
16. CANCER METABOLISM-BASED THERAPIES MARKET, BY GEOGRAPHY
16.1. Cancer Metabolism-Based Therapies Market: Distribution by Geography
16.1.1. Cancer Metabolism-Based Therapies Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.1.1. Cancer Metabolism-Based Therapies Market in the US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.1.2. Cancer Metabolism-Based Therapies Market in Canada: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.2. Cancer Metabolism-Based Therapies Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.2.1. Cancer Metabolism-Based Therapies Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.2.2. Cancer Metabolism-Based Therapies Market in the France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.2.3. Cancer Metabolism-Based Therapies Market in UK: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.2.4. Cancer Metabolism-Based Therapies Market in Italy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.2.5. Cancer Metabolism-Based Therapies Market in Spain: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.2.6. Cancer Metabolism-Based Therapies Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.3. Cancer Metabolism-Based Therapies Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.3.1. Cancer Metabolism-Based Therapies Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.3.2. Cancer Metabolism-Based Therapies Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.3.3. Cancer Metabolism-Based Therapies Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.3.4. Cancer Metabolism-Based Therapies Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.3.5. Cancer Metabolism-Based Therapies Market in Rest of Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
16.1.3.6. Cancer Metabolism-Based Therapies Market in Rest of the World: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17. CANCER METABOLISM-BASED THERAPIES MARKET, NORTH AMERICA
17.1. Cancer Metabolism-Based Therapies Market in North America: Distribution by Type of Modality
17.1.1. Cancer Metabolism-Based Therapies Market in North America for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.1.2. Cancer Metabolism-Based Therapies Market in North America for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.2. Cancer Metabolism-Based Therapies Market in North America: Distribution by Route of Administration
17.2.1. Cancer Metabolism-Based Therapies Market in North America for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.2.2. Cancer Metabolism-Based Therapies Market in North America for Intramuscular Route: Forecasted Estimates (Till 2035)
17.2.3. Cancer Metabolism-Based Therapies Market in North America for Intravenous Route: Forecasted Estimates (Till 2035)
17.3. Cancer Metabolism-Based Therapies Market in North America: Distribution by Target Disease Indication
17.3.1. Cancer Metabolism-Based Therapies Market in North America for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.3.2. Cancer Metabolism-Based Therapies Market in North America for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.3.3. Cancer Metabolism-Based Therapies Market in North America for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.3.4. Cancer Metabolism-Based Therapies Market in North America for Brain Cancer: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)
17.3.5. Cancer Metabolism-Based Therapies Market in North America for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.3.6. Cancer Metabolism-Based Therapies Market in North America for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.7. Cancer Metabolism-Based Therapies Market in North America for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
17.3.8. Cancer Metabolism-Based Therapies Market in North America for Malignant-mesothelioma: Forecasted Estimates (Till 2035)
17.3.9. Cancer Metabolism-Based Therapies Market in North America for Pancreatic Cancer: Forecasted Estimates (Till 2035)
17.3.10. Cancer Metabolism-Based Therapies Market in North America for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035)
17.3.11. Cancer Metabolism-Based Therapies Market in North America for Hepatocellular Carcinoma: Forecasted Estimates (Till 2035)
18. CANCER METABOLISM-BASED THERAPIES MARKET, EUROPE
18.1. Cancer Metabolism-Based Therapies Market in Europe: Distribution by Type of Modality
18.1.1. Cancer Metabolism-Based Therapies Market in Europe for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
18.1.2. Cancer Metabolism-Based Therapies Market in Europe for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
18.2. Cancer Metabolism-Based Therapies Market in Europe: Distribution by Route of Administration
18.2.1. Cancer Metabolism-Based Therapies Market in Europe for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
18.2.2. Cancer Metabolism-Based Therapies Market in Europe for Intramuscular Route: Forecasted Estimates (Till 2035)
18.2.3. Cancer Metabolism-Based Therapies Market in Europe for Intravenous Route: Forecasted Estimates (Till 2035)
18.3. Cancer Metabolism-Based Therapies Market in Europe: Distribution by Target Disease Indication
18.3.1. Cancer Metabolism-Based Therapies Market in Europe for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
18.3.2. Cancer Metabolism-Based Therapies Market in Europe for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
18.3.3. Cancer Metabolism-Based Therapies Market in Europe for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
18.3.4. Cancer Metabolism-Based Therapies Market in Europe for Brain Cancer: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)
18.3.5. Cancer Metabolism-Based Therapies Market in Europe for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
18.3.6. Cancer Metabolism-Based Therapies Market in Europe for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.3.7. Cancer Metabolism-Based Therapies Market in Europe for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
18.3.8. Cancer Metabolism-Based Therapies Market in Europe for Malignant-mesothelioma: Forecasted Estimates (Till 2035)
18.3.9. Cancer Metabolism-Based Therapies Market in Europe for Pancreatic Cancer: Forecasted Estimates (Till 2035)
18.3.10. Cancer Metabolism-Based Therapies Market in Europe for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035)
18.3.11. Cancer Metabolism-Based Therapies Market in Europe for Hepatocellular Carcinoma: Forecasted Estimates (Till 2035)
19. CANCER METABOLISM-BASED THERAPIES MARKET, ASIA-PACIFIC
19.1. Cancer Metabolism-Based Therapies Market in Asia-Pacific: Distribution by Type of Modality
19.1.1. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
19.1.2. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
19.2. Cancer Metabolism-Based Therapies Market in Asia-Pacific: Distribution by Route of Administration
19.2.1. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
19.2.2. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Intramuscular Route: Forecasted Estimates (Till 2035)
19.2.3. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Intravenous Route: Forecasted Estimates (Till 2035)
19.3. Cancer Metabolism-Based Therapies Market in Asia-Pacific: Distribution by Target Disease Indication
19.3.1. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
19.3.2. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
19.3.3. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
19.3.4. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Brain Cancer: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)
19.3.5. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
19.3.6. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
19.3.7. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
19.3.8. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Malignant-mesothelioma: Forecasted Estimates (Till 2035)
19.3.9. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Pancreatic Cancer: Forecasted Estimates (Till 2035)
19.3.10. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035)
19.3.11. Cancer Metabolism-Based Therapies Market in Asia-Pacific for Hepatocellular Carcinoma: Forecasted Estimates (Till 2035)
Detailed segment-wise distribution across individual regions is available in supporting excel data packs
20. CANCER METABOLISM-BASED THERAPIES MARKET, SALES FORECAST OF DRUGS
20.1. Approved Cancer Metabolism-Based Therapies: Sales Forecast
20.1.1. Daraxonrasib: Sales Forecast
20.1.2. Gedatolisib: Sales Forecast
20.1.3. Olomorasib: Sales Forecast
20.1.4. Inavolisib: Sales Forecast
20.1.5. Vorasidenib: Sales Forecast
20.1.6. STX-478: Sales Forecast
20.1.7. AZD 5363: Sales Forecast
20.1.8. AG-120: Sales Forecast
20.1.9. Selpercatinib: Sales Forecast
20.1.10. ADI-PEG 20: Sales Forecast
20.1.11. Augtyro: Sales Forecast
20.1.12. Taletrectinib: Sales Forecast
20.1.13. Piqray / Vijoice: Sales Forecast
20.1.14. TAS-120: Sales Forecast
20.1.15. Rezlidhia: Sales Forecast
20.1.16. AG-221: Sales Forecast
21. CONCLUDING REMARKS
22. EXECUTIVE INSIGHTS
22.1. Chapter Overview
22.2. Company A
22.2.1. Company Snapshot
22.2.2. Interview Transcript: Associate Professor
22.3. Company B
22.3.1. Company Snapshot
22.3.2. Interview Transcript: Medical Oncologist
22.4. Company C
22.4.1. Company Snapshot
22.4.2. Interview Transcript: Associate Professor
23. APPENDIX I: TABULATED DATA
24. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 7.1 Cancer Metabolism-based Therapy Programs: Distribution by Stage of Development
Figure 7.2 Cancer Metabolism-based Therapy Programs: Distribution by Metabolic Pathway
Figure 7.3 Cancer Metabolism-based Therapy Programs: Distribution by Target
Figure 7.4 Cancer Metabolism-based Therapy Programs: Distribution by Target Disease Indication
Figure 7.5 Cancer Metabolism-based Therapy Programs: Distribution by Route of Administration
Figure 7.6 Cancer Metabolism-based Therapy Programs: Distribution by Type of Modality
Figure 7.7 Cancer Metabolism-based Therapy Programs: Distribution by Type of Therapy
Figure 7.8 Cancer Metabolism-based Therapy Programs: Distribution by Drug Designation
Figure 7.9 Cancer Metabolism-based Therapy Developers: Distribution by Year of Establishment
Figure 7.10 Cancer Metabolism-based Therapy Developers: Distribution by Company Size
Figure 7.11 Cancer Metabolism-based Therapy Developers: Distribution by Location of Headquarters
Figure 7.12 Cancer Metabolism-based Therapy Developers: Distribution by Company Size and Location of Headquarters
Figure 7.13 Most Active Players: Analysis by Number of Therapies
Figure 9.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 9.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 9.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 9.4 Clinical Trial Analysis: Distribution by Patients Enrolled by Trial Registration Year
Figure 9.5 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status
Figure 9.6 Clinical Trial Analysis: Distribution of Trials by Trial Phase
Figure 9.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 9.8 Clinical Trial Analysis: Distribution by Study Design
Figure 9.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 9.10 Clinical Trial Analysis: Distribution by Patient Gender
Figure 9.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 9.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 9.13 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Figure 9.14 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 9.15 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Figure 9.16 Clinical Trial Analysis: Geographical Distribution of Trials and Number of Patients Enrolled
Figure 9.17 Clinical Trial Analysis in North America: Key Insights
Figure 9.18 Clinical Trial Analysis in Europe: Key Insights
Figure 9.19 Clinical Trial Analysis in Asia-Pacific: Key Insights
Figure 9.20 Clinical Trial Analysis in Rest of the World: Key Insights
Figure 10.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Target Disease Indication
Figure 10.5 Most Active Players: Distribution by Number of Partnerships
Figure 10.6 Partnerships and Collaborations: Local and International Deals
Figure 10.7 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Figure 10.8 Partnerships and Collaborations: Recent Examples
Figure 12.1 Global Cancer Metabolism-Based Therapies Market: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 12.2 Global Cancer Metabolism-Based Therapies Market: Forecasted Estimates (Till 2035) (USD Billion), Conservative Scenario
Figure 12.3 Global Cancer Metabolism-Based Therapies Market: Forecasted Estimates (Till 2035) (USD Billion), Optimistic Scenario
Figure 13.1 Cancer Metabolism-Based Therapies Market for Biologics: Forecasted Estimates (Till 2035) (USD Billion)
Figure 13.2 Cancer Metabolism-Based Therapies Market for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
Figure 14.1 Cancer Metabolism-Based Therapies Market for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 14.2 Cancer Metabolism-Based Therapies Market for Intramuscular Route: Forecasted Estimates (Till 2035) (USD Billion)
Figure 14.3 Cancer Metabolism-Based Therapies Market for Intravenous Route: Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.1 Cancer Metabolism-Based Therapies Market for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.2 Cancer Metabolism-Based Therapies Market for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.3 Cancer Metabolism-Based Therapies Market for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.4 Cancer Metabolism-Based Therapies Market for Brain Cancer: Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.5 Cancer Metabolism-Based Therapies Market for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.6 Cancer Metabolism-Based Therapies Market for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.7 Cancer Metabolism-Based Therapies Market for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.8 Cancer Metabolism-Based Therapies Market for Others: Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.9 Cancer Metabolism-Based Therapies Market for Malignant-mesothelioma: Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.10 Cancer Metabolism-Based Therapies Market for Pancreatic Cancer: Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.11 Cancer Metabolism-Based Therapies Market for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035) (USD Billion)
Figure 15.12 Cancer Metabolism-Based Therapies Market for Hepatocellular Cancer: Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.1 Cancer Metabolism-Based Therapies Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.2 Cancer Metabolism-Based Therapies Market in US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.3 Cancer Metabolism-Based Therapies Market in Canada: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.4 Cancer Metabolism-Based Therapies Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.5 Cancer Metabolism-Based Therapies Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.6 Cancer Metabolism-Based Therapies Market in France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.7 Cancer Metabolism-Based Therapies Market in UK: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.8 Cancer Metabolism-Based Therapies Market in Italy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.9 Cancer Metabolism-Based Therapies Market in Spain: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.10 Cancer Metabolism-Based Therapies Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.11 Cancer Metabolism-Based Therapies Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.12 Cancer Metabolism-Based Therapies Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.13 Cancer Metabolism-Based Therapies Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.14 Cancer Metabolism-Based Therapies Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.15 Cancer Metabolism-Based Therapies Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.16 Cancer Metabolism-Based Therapies Market in Rest of Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 16.17 Cancer Metabolism-Based Therapies Market in Rest of the World: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.1 Cancer Metabolism-Based Therapies Market Daraxonrasib: Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.2 Cancer Metabolism-Based Therapies Market Gedatolisib: Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.3 Cancer Metabolism-Based Therapies Market Olomorasib: Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.4 Cancer Metabolism-Based Therapies Market Inavolisib: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.5 Cancer Metabolism-Based Therapies Market Vorasidenib: Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.6 Cancer Metabolism-Based Therapies Market STX-478: Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.7 Cancer Metabolism-Based Therapies Market AZD 5363: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.8 Cancer Metabolism-Based Therapies Market AG-120: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.9 Cancer Metabolism-Based Therapies Market Selpercatinib: Historical Trends (Since 2021) Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.10 Cancer Metabolism-Based Therapies Market ADI-PEG 20: Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.11 Cancer Metabolism-Based Therapies Market AUGTYRO: Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.12 Cancer Metabolism-Based Therapies Market Taletrectinib: Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.13 Cancer Metabolism-Based Therapies Market Piqray / Vijoice: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.14 Cancer Metabolism-Based Therapies Market TAS-120: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.15 Cancer Metabolism-Based Therapies Market REZLIDHIA: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.16 Cancer Metabolism-Based Therapies Market AG-221: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 7.1 List of Cancer Metabolism-Based Therapy Programs
Table 7.2 List of Cancer Metabolism-Based Therapies Developers
Table 9.1 Cancer Metabolism-Based Therapies: List of Clinical Trials
Table 10.1 Cancer Metabolism-Based Therapies: List of Partnership and Collaborations
Table 12.1 Global Cancer Metabolism-Based Therapies Market, till 2035: List of Cancer Metabolism-based Therapies Forecasted
Table 23.1 Cancer Metabolism-Based Therapies: Distribution by Stage of Development
Table 23.2 Cancer Metabolism-Based Therapies: Distribution by Metabolic Pathway
Table 23.3 Cancer Metabolism-Based Therapies: Distribution by Target
Table 23.4 Cancer Metabolism-Based Therapies: Distribution by Therapeutic Indication
Table 23.5 Cancer Metabolism-Based Therapies: Distribution by Route of Administration
Table 23.6 Cancer Metabolism-Based Therapies: Distribution by Type of Modality
Table 23.7 Cancer Metabolism-Based Therapies: Distribution by Type of Therapy
Table 23.8 Cancer Metabolism-Based Therapies: Distribution by Drug Designation
Table 23.9 Cancer Metabolism-Based Therapy Developers: Distribution by Year of Establishment
Table 23.10 Cancer Metabolism-Based Therapy Developers: Distribution by Company Size
Table 23.11 Cancer Metabolism-Based Therapy Developers: Distribution by Location of Headquarters
Table 23.12 Cancer Metabolism-Based Therapy Developers: Distribution by Company Size and Location of Headquarters
Table 23.13 Most Active Players: Analysis by Number of Therapies
Table 23.14 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 23.15 Clinical Trial Analysis: Distribution by Trial Status
Table 23.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 23.17 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Table 23.18 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Table 23.19 Clinical Trial Analysis: Distribution by Trial Phase
Table 23.20 Clinical Trial Analysis: Distribution by Patients Enrolled and Trial Phase
Table 23.21 Clinical Trial Analysis: Distribution by Study Design
Table 23.22 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 23.23 Clinical Trial Analysis: Distribution by Patient Gender
Table 23.24 Most Active Industry Players: Distribution by Number of Trials
Table 23.25 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 23.26 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Table 23.27 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Table 23.28 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Table 23.29 Clinical Trial Analysis in North America: Key Insights
Table 23.30 Clinical Trial Analysis in Europe: Key Insights
Table 23.31 Clinical Trial Analysis in Asia-Pacific: Key Insights
Table 23.32 Clinical Trial Analysis in Rest of the World: Key Insights
Table 23.33 Partnerships and Collaborations: Distribution by Year of Partnership
Table 23.34 Partnerships and Collaborations: Distribution by Type of Partnership
Table 23.35 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 23.36 Partnerships and Collaborations: Distribution by Target Disease Indication
Table 23.37 Most Active Players: Distribution by Number of Partnerships
Table 23.38 Partnerships and Collaborations: Local and International Deals
Table 23.39 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Table 23.40 Global Cancer Metabolism-Based Therapies Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.41 Global Cancer Metabolism-Based Therapies Market, Forecasted Estimates (Till 2035) (USD Billion), Conservative Scenario
Table 23.42 Global Cancer Metabolism-Based Therapies Market, Forecasted Estimates (Till 2035) (USD Billion), Optimistic Scenario
Table 23.43 Cancer Metabolism-Based Therapies Market: Distribution by Type of Modality
Table 23.44 Cancer Metabolism-Based Therapies Market for Biologics, Forecasted Estimates (Till 2035) (USD Billion)
Table 23.45 Cancer Metabolism-Based Therapies Market for Small Molecules, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.46 Cancer Metabolism-Based Therapies Market: Distribution by Route of Administration
Table 23.47 Cancer Metabolism-Based Therapies Market for Oral Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.48 Cancer Metabolism-Based Therapies Market for Intramuscular Route, Forecasted Estimates (Till 2035) (USD Billion)
Table 23.49 Cancer Metabolism-Based Therapies Market for Intravenous Route, Forecasted Estimates (Till 2035) (USD Billion)
Table 23.50 Cancer Metabolism-Based Therapies Market: Distribution by Target Disease Indication
Table 23.51 Cancer Metabolism-Based Therapies Market for Breast Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.52 Cancer Metabolism-Based Therapies Market for Non-small Cell Lung Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.53 Cancer Metabolism-Based Therapies Market for Acute Myeloid Leukemia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.54 Cancer Metabolism-Based Therapies Market for Brain Cancer, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.55 Cancer Metabolism-Based Therapies Market for Cholangiocarcinoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.56 Cancer Metabolism-Based Therapies Market for Bile Duct Cancer, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.57 Cancer Metabolism-Based Therapies Market for Myelodysplastic Syndromes, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.58 Cancer Metabolism-Based Therapies Market for Malignant-mesothelioma, Forecasted Estimates (Till 2035) (USD Billion)
Table 23.59 Cancer Metabolism-Based Therapies Market for Pancreatic Cancer, Forecasted Estimates (Till 2035) (USD Billion)
Table 23.60 Cancer Metabolism-Based Therapies Market for Soft Tissue Sarcoma, Forecasted Estimates (Till 2035) (USD Billion)
Table 23.61 Cancer Metabolism-Based Therapies Market for Hepatocellular Cancer, Forecasted Estimates (Till 2035) (USD Billion)
Table 23.62 Cancer Metabolism-Based Therapies Market: Distribution by Geographical Regions
Table 23.63 Cancer Metabolism-Based Therapies Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.64 Cancer Metabolism-Based Therapies Market in US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.65 Cancer Metabolism-Based Therapies Market in Canada, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.66 Cancer Metabolism-Based Therapies Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.67 Cancer Metabolism-Based Therapies Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.68 Cancer Metabolism-Based Therapies Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.69 Cancer Metabolism-Based Therapies Market in UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.70 Cancer Metabolism-Based Therapies Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.71 Cancer Metabolism-Based Therapies Market in Spain, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.72 Cancer Metabolism-Based Therapies Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.73 Cancer Metabolism-Based Therapies Market in Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.74 Cancer Metabolism-Based Therapies Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.75 Cancer Metabolism-Based Therapies Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.76 Cancer Metabolism-Based Therapies Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.77 Cancer Metabolism-Based Therapies Market in South Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.78 Cancer Metabolism-Based Therapies Market in Rest of Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.79 Cancer Metabolism-Based Therapies Market in Rest of the World, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.80 Cancer Metabolism-Based Therapies Market Daraxonrasib, Forecasted Estimates (Till 2035) (USD Billion)
Table 23.81 Cancer Metabolism-Based Therapies Market Gedatolisib, Forecasted Estimates (Till 2035) (USD Billion)
Table 23.82 Cancer Metabolism-Based Therapies Market Olomorasib, Forecasted Estimates (Till 2035) (USD Billion)
Table 23.83 Cancer Metabolism-Based Therapies Market Inavolisib, Historical Trends (Since 2025) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.84 Cancer Metabolism-Based Therapies Market Vorasidenib, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.85 Cancer Metabolism-Based Therapies Market STX-478, Forecasted Estimates (Till 2035) (USD Billion)
Table 23.86 Cancer Metabolism-Based Therapies Market AZD 5363, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.87 Cancer Metabolism-Based Therapies Market AG-120, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.88 Cancer Metabolism-Based Therapies Market Selpercatinib, Historical Trends (Since 2021) Forecasted Estimates (Till 2035) (USD Billion)
Table 23.89 Cancer Metabolism-Based Therapies Market ADI-PEG 20, Forecasted Estimates (Till 2035) (USD Billion)
Table 23.90 Cancer Metabolism-Based Therapies Market AUGTYRO, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.91 Cancer Metabolism-Based Therapies Market Taletrectinib, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.92 Cancer Metabolism-Based Therapies Market Piqray / Vijoice, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.93 Cancer Metabolism-Based Therapies Market TAS-120, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.94 Cancer Metabolism-Based Therapies Market REZLIDHIA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Table 23.95 Cancer Metabolism-Based Therapies Market AG-221, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Please reach out to our team for exhaustive list of companies and relavant details.